The office building of Medtronic Inc., an American medical technology company, is being pictured in ... [+] Shanghai, China, on July 23, 2024. (Photo by Costfoto/NurPhoto via Getty Images)NurPhoto via Getty ImagesMedtronic (NYSE: MDT) is scheduled to report its fiscal 2025 first-quarter results on Tuesday, August 20 (fiscal year ends in April). We expect Medtronic stock to trade higher post-Q1 results announcement, with its revenues and earnings expected to be slightly above the street estimates. The compan ...

GALWAY, Ireland, Aug. 16, 2024 /PRNewswire/ -- The board of directors of Medtronic plc (NYSE:MDT) on Thursday, August 15, 2024, approved the company's cash dividend for the second quarter of fiscal year 2025 of $0.70 per ordinary share. This quarterly declaration is consistent with the dividend increase announcement made by the company in May 2024. Medtronic is a constituent of the S&P 500 Dividend Aristocrats index, having increased its annual dividend payment for the past 47 consecutive years. The dividen ...

Medtronic (MDT) recently announced two major developments within its diabetes care business. The company received FDA approval for its Simplera continuous glucose monitor (CGM), which marks a significant step forward in diabetes management.Along with the FDA approval, Medtronic announced a global partnership with another MedTech stalwart, Abbott (ABT) . Considering the fact that the global diabetes care market has shown remarkable growth over the past few years, this partnership is expected to be strategica ...

Core Insights - Medtronic (MDT) is expected to report quarterly earnings of $1.20 per share, unchanged from the same period last year, with revenues forecasted at $7.9 billion, reflecting a year-over-year increase of 2.5% [1] - The consensus EPS estimate has remained stable over the past 30 days, indicating analysts' reassessment of their projections [1] Revenue Estimates - Analysts predict 'Net Sales- World Wide Revenue- Cardiovascular' to be $2.92 billion, a year-over-year increase of 2.6% [2] - 'Net Sales- World Wide Revenue- Diabetes' is expected to reach $613.04 million, indicating a 6.1% increase year over year [2] - 'Net Sales- World Wide Revenue- Medical Surgical' is estimated at $2.06 billion, reflecting a 1.1% year-over-year change [2] Additional Revenue Projections - 'Net Sales- World Wide Revenue- Neuroscience' is projected at $2.29 billion, showing a 3.3% increase from the prior-year quarter [3] - 'Net Sales- U.S. Revenue' is expected to be $4.03 billion, indicating a 2.6% change from the year-ago quarter [3] - 'Net Sales- ROW- Cardiovascular- Structural Heart & Aortic' is forecasted at $480.82 million, reflecting a 5.2% increase year over year [3] Regional and Segment Revenue Insights - 'Net Sales- ROW- Cardiovascular' is projected to reach $1.55 billion, indicating a year-over-year change of 3.6% [4] - 'Net Sales- U.S. Revenue- Cardiovascular- Cardiac Rhythm & Heart Failure' is estimated at $734.17 million, reflecting a 2% change from the prior-year quarter [4] - 'Net Sales- U.S. Revenue- Cardiovascular' is expected to be $1.37 billion, indicating a 1.5% increase from the year-ago quarter [4] Stock Performance - Over the past month, Medtronic shares have returned +0.6%, while the Zacks S&P 500 composite has decreased by -2.9% [4] - Medtronic currently holds a Zacks Rank 4 (Sell), suggesting potential underperformance relative to the overall market in the near future [4]

ab 14 August 2024 Global Research and Evidence Lab Medtronic PLC Diabetes Turnaround Sustainable, Clearing Path to MSD Sales Growth; U/G to Neutral CGM Partnership Potentially Transformative for MDT Diabetes We are upgrading MDT to Neutral from Sell as we now have higher conviction that the recent Diabetes turnaround is sustainable. With Diabetes representing just under 10% of MDT's sales but also one of MDT's higher growth end markets, this business is critical to MDT's top-line growth trajectory. With thi ...

Medtronic (MDT) closed the most recent trading day at $82.27, moving +1.33% from the previous trading session. The stock fell short of the S&P 500, which registered a gain of 1.69% for the day. At the same time, the Dow added 1.04%, and the tech-heavy Nasdaq gained 2.43%.Shares of the medical device company have appreciated by 5.33% over the course of the past month, outperforming the Medical sector's loss of 0.57% and the S&P 500's loss of 4.78%.The investment community will be closely monitoring the perfo ...

GALWAY, Ireland, Aug. 12, 2024 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its first quarter of fiscal year 2025 on Tuesday, August 20, 2024. A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https://news.medtronic.com. The news release will include summary financial information for the company's first quarter of fiscal year 2025, which ended on Friday ...

Core Viewpoint - Federated Hermes, Inc. announced a proposed change in the diversification policy of its Federated Hermes MDT Large Cap Growth ETF, shifting from a diversified to a non-diversified company, pending shareholder approval [1][2]. Group 1: Fund Policy Change - The Board of Trustees approved the change in fundamental policy regarding diversification, which requires majority shareholder consent [1]. - The record date for determining shareholder consent is set for August 19, 2024, with the decision expected on August 23, 2024 [1][2]. - The change is anticipated to be effective on August 26, 2024, if approved by written consent [2]. Group 2: Investment Strategy - The Fund aims to approximate exposure to companies in the Russell 1000® Growth Index, although it is not designed to track the Index's overall composition or returns [3]. - The diversification classification change is intended to provide greater long-term flexibility in executing the investment strategy, especially when individual issuer weightings exceed diversification limits under the Investment Company Act of 1940 [3]. - The fundamental policy change is not expected to significantly impact the Fund's principal investment strategies [3]. Group 3: Company Overview - Federated Hermes, Inc. is a global leader in active investment management, with $782.7 billion in assets under management as of June 30, 2024 [4]. - The company provides a range of investment solutions, including equity, fixed-income, alternative/private markets, multi-asset, and liquidity management strategies to over 10,000 institutions and intermediaries worldwide [4]. - Headquartered in Pittsburgh, Federated Hermes employs more than 2,000 people across various global offices [4].

Medtronic Diabetes expands CGM offerings to meet more people where they are in their diabetes journey DUBLIN, Aug. 7, 2024 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) approval for its Simplera™ continuous glucose monitor (CGM) — the company's first disposable, all-in-one CGM that's half the size of previous Medtronic CGMs. The discreet design simplifies the insertion and wear experience, eliminating the need ...

These two are rock-solid businesses with strong dividend programs.Every corporation will face challenges and setbacks -- which will sometimes sink its stock price. That's not a good reason for long-term investors to jump ship unless, of course, there's a fundamental shift in the company's prospects.Stocks that can perform reasonably well while maintaining a positive long-term outlook may well be worth holding onto for good. Corporations in this category are common, but they do exist; two examples are Merck ...